# Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy

> **NCT00001440** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (—)

## Conditions studied

- Breast Neoplasm
- Neoplasm Metastasis

## Interventions

- **PROCEDURE:** Autologous T cells
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT00001440
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-07
- **Primary completion:** —
- **Final completion:** 2002-01
- **Target enrollment:** 51 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001440, "Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00001440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*